Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26477127 | 0.87 | PIK3CA (0.45) | PIK3CAKDM4EALOX15ALDH1A1HPGD | |
| SCHEMBL22718319 | 0.82 | KMO (0.44) | PIK3CAKDM4EALDH1A1HPGDPOLB | |
| SCHEMBL27009137 | 0.80 | HPGD (0.53) | KDM4EALDH1A1HPGDPOLBLMNA | |
| SCHEMBL2437695 | 0.80 | KDM4E (0.46) | KDM4EALDH1A1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL24378546 | 0.79 | DPP4 (0.45) | PIK3CAKDM4EALOX15ALDH1A1HPGD | |
| SCHEMBL27009158 | 0.79 | PIK3CA (0.49) | PIK3CAKDM4EALOX15ALDH1A1HPGD | |
| SCHEMBL23666006 | 0.79 | KDM4E (0.40) | PIK3CAKDM4EALOX15ALDH1A1HPGD | |
| SCHEMBL2436756 | 0.79 | PDE4B (0.42) | KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL24378656 | 0.78 | ALDH1A1 (0.42) | PIK3CAKDM4EALDH1A1HPGDPOLB | |
| SCHEMBL27009144 | 0.78 | HPGD (0.49) | PIK3CAKDM4EALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115209952-B | Substituted pyrazolopyrimidines and use thereof | 维基分析有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| EP-4229063-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230133203-A1 | Substituted Pyrazolo-Pyrimidines and Uses Thereof | Verge Analytics, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4165045-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | Monash University (AU) | 2023-04-19 | — | — | EP | disclosed |
| WO-2022261069-A1 | METHODS AND TREATMENT OF VIRAL INFECTION WITH SUBSTITUTED PYRAZOLO-PYRIMIDINES | Verge Analytics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4090426-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220168315-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC | 2022-06-02 | — | — | US | disclosed |
| US-20220168315-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC | 2022-06-02 | — | — | US | disclosed |
| WO-2022086993-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022086993-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021146192-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021146192-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2020243457-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243457-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC (US) | 2020-12-03 | — | — | WO | disclosed |
| US-8314098-B2 | Pyrazolo-pyrimidine compounds | AJINOMOTO CO., INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110294781-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS | AJINOMOTO CO., INC. (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294781-A1 | PYRAZOLO-PYRIMIDINE COMPOUNDS | IL23R, IL2, IL17A | PIK3CA 1490/4885KDM4E 4325/4885ALOX15 132/4885 |
| US-20230133203-A1 | Substituted Pyrazolo-Pyrimidines and Uses Thereof | PIKFYVE, PIP4K2B, PIP4K2C | PIK3CA 10/4885KDM4E 1122/4885ALOX15 4746/4885 |
| US-20220168315-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | IL15, IL17A, IL2 | PIK3CA 2666/4885KDM4E 3834/4885ALOX15 97/4885 |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | PIK3CA 11/4885KDM4E 1460/4885ALOX15 3483/4885 |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MAP2K2, BRPF3, BRDT | PIK3CA 574/4885KDM4E 866/4885ALOX15 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.